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Abstract
Background and purpose: Short- interval intracortical inhibition by threshold tracking 
(T- SICI) has been proposed as a diagnostic tool for amyotrophic lateral sclerosis (ALS) 
but has not been compared directly with conventional amplitude measurements (A- 
SICI). This study compared A- SICI and T- SICI for sensitivity and clinical usefulness as 
biomarkers for ALS.
Methods: In all, 104 consecutive patients referred with suspicion of ALS were prospec-
tively included and were subsequently divided into 62 patients with motor neuron dis-
ease (MND) and 42 patient controls (ALS mimics) by clinical follow- up. T- SICI and A- SICI 
recorded in the first dorsal interosseus muscle (index test) were compared with record-
ings from 53 age- matched healthy controls. The reference standard was the Awaji crite-
ria. Clinical scorings, conventional nerve conduction studies and electromyography were 
also performed on the patients.
Results: Motor neuron disease patients had significantly reduced T- SICI and A- SICI 
compared with the healthy and patient control groups, which were similar. Sensitivity 
and specificity for discriminating MND patients from patient controls were high (areas 
under the receiver operating characteristic curves 0.762 and 0.810 for T- SICI and A- SICI 
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INTRODUC TION
Amyotrophic lateral sclerosis (ALS) is a devastating disease, without 
well- known aetiology or risk factors [1– 5] and with progressive in-
volvement of upper motor neurons (UMNs) and lower motor neurons 
(LMNs). The diagnosis is made clinically, and patients are categorized 
as definite, probable or possible ALS, depending on the distribution 
of body regions with clinical or electrophysiological signs of LMN 
degeneration and UMN involvement [6,7]. Patients presenting solely 
with LMN involvement are classified as progressive muscular atro-
phy (PMA) and are not considered as ALS according to the revised 
El- Escorial [8] or Awaji criteria [6]. Overt or subclinical LMN affec-
tion can be reliably detected by routine neurophysiological tech-
niques, notably needle electromyography (EMG). However, there is 
currently no consensus on the value of electrodiagnostic methods 
to assess subclinical UMN involvement, so that only UMN clinical 
signs are accepted in the ALS diagnostic criteria. This may result in 
delays to diagnosis and commencement of adequate management 
strategies and recruitment into therapeutic trials.
Single- pulse transcranial magnetic stimulation (TMS) tech-
niques have low diagnostic sensitivity in ALS [9,10] unless the F- 
wave method [11] or proximal muscle recordings [12] are used. By 
contrast, abnormalities can be more readily detected by paired- 
pulse TMS protocols, such as short- interval intracortical inhibition 
(SICI), when a preceding subthreshold conditioning stimulus given 
at an inter- stimulus interval (ISI) of 1– 5 ms reduces the amplitude 
of the response to a suprathreshold test stimulus [13]. A reduction 
of this amplitude- based measure of cortical inhibition (A- SICI) was 
first described in a small cohort of 14 ALS patients [14]. Later, a se-
rial threshold tracking SICI (T- SICI) methodology was introduced, 
whereby a target motor evoked potential (MEP) amplitude is tracked 
and the changes in stimulus intensity in response to subthreshold 
conditioning stimuli are recorded [15]. This method has been widely 
used by one group and has been shown to have a high diagnostic 
utility [10,16– 18], and it has been advocated as a potential biomarker 
for ALS [18,19]. However, these findings have never been confirmed 
by other research groups [20] or compared directly with conven-
tional A- SICI measurements.
A recent study found that the serial T- SICI method distorted 
the relationship between inhibition and ISI [21]. This distortion was 
avoided by using a parallel T- SICI method, previously used to as-
sess dependence of SICI on conditioning stimulus intensity [22]. 
Parallel T- SICI also estimated inhibition with less variability than 
serial T- SICI, although not as little as was achieved by A- SICI [21].
The clinical diagnostic sensitivity and specificity of A- SICI and 
T- SICI (using the new parallel method) were therefore compared in 
a cohort of well- characterized patients referred with the suspicion 
of ALS, in whom the diagnoses were confirmed or excluded by clini-
cal follow- up. The findings of T- SICI and A- SICI were also correlated 
with the clinical presentations of the patients, to detect any differ-
ences in specificity that might provide insights into the pathophysi-
ology of the disease.
METHODS
Subjects
This study included prospectively consecutive patients referred with 
the suspicion of ALS in accordance with the Standards for Reporting 
of Diagnostic Accuracy (STARD) criteria [23] and applied the index 
test and reference standard to all patients at the time of recruitment. 
None of the patients had been diagnosed with the disease before re-
cruitment; therefore none of the patients was receiving riluzole. All 
examinations were undertaken at Aarhus University Hospital. Only 
right- handed subjects were included. Exclusion criteria were the use 
of drugs that could affect cortical excitability, history of epilepsy, 
known dementia and presence of a pacemaker or other metallic bio-
medical device.
In total, 133 patients were eligible for inclusion and accepted 
to participate between April 2018 and September 2020 (Figure 1). 
Of these, 24 patients were excluded because SICI could not be re-
corded. These patients were more advanced with mostly probable 
and definite ALS (Figure 1), which is consistent with a previous study 
[24]. Five patients were excluded because of inconclusive follow- up 
diagnosis. The final study cohort of 104 patients comprised two 
respectively at 1– 3.5 ms). Paradoxically, T- SICI was most reduced in MND patients with 
the fewest upper motor neuron (UMN) signs (Spearman ρ = 0.565, p = 4.3 × 10−6).
Conclusions: Amplitude- based measure of cortical inhibition and T- SICI are both sensi-
tive measures for the detection of cortical involvement in MND patients and may help 
early diagnosis of ALS, with T- SICI most abnormal before UMN signs have developed. The 
gradation in T- SICI from pathological facilitation in patients with minimal UMN signs to 
inhibition in those with the most UMN signs may be due to progressive degeneration of 
the subset of UMNs experiencing facilitation.
K E Y W O R D S
amyotrophic lateral sclerosis, conventional TMS, short- interval intracortical inhibition, transcranial 
magnetic stimulation, threshold tracking TMS
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groups: motor neuron disease (MND) patients (n = 62) and patient 
controls with mimicking disorders (n = 42). Exclusion of mimic dis-
orders by ancillary investigations and disease progression at the 
clinical follow- up was required to confirm the MND diagnosis. The 
categorization of the MND patients according to Awaji criteria [6] 
was noted at the inclusion. Fifteen patients did not fulfil the ALS 
criteria and were categorized as PMA when they had LMN signs in 
at least two regions (n = 5) or as unclassified MND (n = 10) based 
on the clinical and conventional electrophysiological test results on 
the examination day. The results were compared with 53 healthy 
controls.
In all patients, a detailed clinical examination was performed 
and the clinical scores were noted. T- SICI and A- SICI record-
ings, nerve conduction studies and EMG were carried out in all 
subjects.
All participants gave written informed consent in accordance 
with the Declaration of Helsinki II. The project was approved by the 
local ethical committee (case 1- 10- 72- 201- 17).
Clinical scores
The disease duration (in months) from time of symptom onset and 
the region of onset were noted. UMN involvement was graded using 
a modified Penn UMN score (UMNS), with higher scores (maxi-
mum 27) corresponding to greater disease burden [25,26]. Single 
points were given for an abnormal jaw- jerk reflex, palmomental sign 
and pseudobulbar affect [27]. In the extremities, deep tendon re-
flexes (biceps, triceps, ankle), pathological reflexes (Hoffman´s and 
Babinski´s sign and clonus) and spasticity [28] were scored.
F I G U R E  1  Schematic diagram of 
patient classification. ALS, amyotrophic 
lateral sclerosis; A- SICI, conventional 
amplitude- based SICI; CMAP amp., 
compound action potential amplitude; 
MND- U, motor neuron disease 
unclassified; PLS, primary lateral sclerosis; 
PMA, progressive muscular atrophy; SICI, 
short- interval intracortical inhibition; T- 
SICI, threshold tracking SICI
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Muscle strength using the Medical Research Council (MRC) 
score for shoulder abduction, elbow flexion, wrist extension, index 
finger abduction, thumb abduction, hip flexion, knee extension and 
ankle dorsiflexion was evaluated, yielding a maximum total score of 
80. Disease severity was staged using the revised ALS Functional 
Rating Score (ALSFRS- R) [29] which yields a maximum score of 48.
Nerve conduction studies and electromyography
Conventional methods were performed according to the 
department´s routine [30,31]. The only data presented here are the 
peak- to- peak amplitude recorded from the first dorsal interosseus 
muscle (FDI) and the FDI EMG data. For EMG, the incidence of fi-
brillation potentials, positive sharp waves and fasciculations at 10 
different sites was noted [30] and 20 motor unit potentials were re-
cruited for quantitative analysis.
Transcranial magnetic stimulation
Threshold tracking SICI and A- SICI measurements were performed 
in random order. Subjects were seated comfortably in an armchair 
and asked to relax but keep awake. A figure- of- eight coil (Magstim® 
D70 Remote Coil) connected to two Magstim®200 [2] stimulators 
was positioned at approximately 4 cm left in the binauricular line 
from vertex, with the handle pointing 45° to the parasagittal plane. 
Once the hotspot was located, the outline of the coil was drawn on a 
swimming cap to enable constant coil positioning and the automated 
stimulation protocol was initiated. Stimulus delivery and data acqui-
sition were controlled by QtracW software (© University College 
London) using QTMSG- 12 recording protocols.
The MEPs were measured from the right FDI using disposable 
surface electrodes placed in a belly- tendon fashion. The MEP was 
amplified (1000× gain) and filtered (3 Hz to 3 kHz) using a D440- 2 
Channel Isolated Amplifier (Digitimer Ltd). A 50/60 Hz Humbug Noise 
Eliminator was used to remove line frequency contamination, and the 
amplified signals were digitized (NI USB- 6251, National Instruments).
Resting motor threshold
Resting motor thresholds (RMTs) for a 200 µV (RMT200) or for a 1 mV 
(TS1 mV) peak- to- peak response were detected by a 4 → 2 → 1 track-
ing rule, as previously described [21]. RMTs and all further thresh-
olds, whether conditioned or unconditioned, were estimated from 
the stimuli and responses by weighted logarithmic regression [15,21].
Threshold tracking SICI and A- SICI protocols
For T- SICI the parallel tracking method previously designated T- SICIp2 
was used, in which SICI at each ISI was tracked independently, whilst 
the A- SICI protocol was as described previously [21]. For both meth-
ods, conditioning stimulus amplitude was set to 70% RMT200 but, 
whereas in A- SICI the test stimuli were fixed at TS1 mV, for T- SICI the 
test stimuli tracked the 200 µV target. In both methods test- alone stim-
uli were delivered after each three conditioning + test combinations, 
with the ISIs (1, 1.5, 2, 2.5, 3, 3.5, 4, 5 and 7 ms) presented in pseudo- 
random order. Each of the nine paired stimuli was delivered 10 times, 
making a total of 120 stimuli with the test- alone stimuli.
Data analysis
Recordings were analysed with QtracW software: T- SICI thresholds 
were estimated by log regression and A- SICI amplitudes were av-
eraged as geometric means. A- SICI amplitudes were normalized, to 
overcome the ‘floor’ effect, by log conversion and scaled to become 
comparable with the T- SICI thresholds, using the relationship found 
in the healthy controls (see Results) [21]. Mean SICI values were 
compared between the MND patients and healthy controls as well 
as between MND patients and patient controls using independent 
samples t tests. Correlation analyses were made using parametric 
or non- parametric tests depending on normality. The ability of a 
method to discriminate patients from controls was evaluated by de-
termining the area under the receiver operating characteristic (ROC) 
curve. The age and sex differences between groups were evaluated 
by analysis of variance tests. p < 0.05 was considered significant.
RESULTS
Patient demographics
Of the 104 patients, 62 patients had disease progression at the clinical 
follow- up (up to 2½ years) and were classified as MND patients, whilst 
in 42 patients, designated patient controls, other diagnoses were 
given. Of the 62 MND patients, 47 fulfilled the criteria for ALS (defi-
nite, 1; probable, 20; possible, 26) whilst 15 patients had only LMN in-
volvement confirmed with EMG at the inclusion. In 42 patients, other 
diagnoses were given according to the clinical follow- up (Figure 1). 
The ages of the three main groups were not significantly different 
by analysis of variance (mean ± SD: healthy controls 62.9 ± 12.1, pa-
tient controls 61.1 ± 15.0, MND patients 66.4 ± 10.3; p = 0.081), but 
the ratio of males to females was higher in the patient control group 
(male to female: healthy controls 27/26, patient controls 33/9, MND 
patients 39/23). The mean disease duration for the MND patients was 
11.9 ± 6.4 months, and their mean ALSFRS- R score was 40.5 ± 4.5.
Relationship between A- SICI and T- SICI in 
healthy controls
Figure 2a shows the relationship between all the A- SICI and T- SICI 
measurements on healthy control subjects, that is, 477 measurements, 
3034  |    TANKISI eT Al.
comprising nine ISIs in 53 subjects. As previously described [21] there 
is a strong relationship between T- SICI and log A- SICI amplitude. This 
relationship enables the A- SICI measurements, which exhibit a pro-
nounced ‘floor’ effect (see Figure 2b), to be normalized so that they are 
comparable to the T- SICI measurements by A- SICI- T = 100 − 18.51 × 
log 10(A- SICI/100). These A- SICI- T values are compared for 1– 3.5 ms 
means in Figure 2c, and as for the younger healthy subjects in the pre-
vious study [21] the A- SICI distribution is effectively normalized and 
the A- SICI- T values have less variation between subjects than the T- 
SICI values.
Dependence of T- SICI, A- SICI and A- SICI- T on ISI 
for the three groups
Figure 3 shows the mean A- SICI, A- SICI- T and T- SICI values in MND 
patients, patient controls and healthy controls. Inhibition is shown in 
A- SICI by a reduction of the amplitude but in T- SICI and A- SICI- T by 
an increase in threshold. There was significantly less inhibition in the 
MND patients, compared with either control group, for both T- SICI 
and A- SICI, whereas there was no significant difference between 
the two control groups. The difference between MND patients and 
controls was less for A- SICI- T than for T- SICI, but the variation in A- 
SICI- T values was less than for T- SICI as indicated by the coefficients 
of variation in Figure 4.
Discrimination between controls and MND patients 
by A- SICI and T- SICI
Figure 3 shows that both A- SICI and T- SICI discriminated clearly be-
tween MND patients and both control groups. A better idea of the 
degree to which individuals were discriminated is given by the exam-
ples of mean thresholds from 1 to 3.5 ms in Figure 5. The sensitivity 
and specificity of the techniques as diagnostic tools is best com-
pared by the areas under ROC curves (ROC AUCs), which are given 
in Table 1. For SICI averaged from 1 to 3.5 ms, discrimination be-
tween patient controls and MND patients can be regarded as ‘good’ 
(AUCs ~ 0.8) by both methods. However, it is patients with LMN 
signs but insufficient UMN signs to be classified as ALS for whom a 
new UMN biomarker would be most useful, and Table 1 (right side) 
shows that for these the discrimination is even better (AUCs close 
to 0.9).
Nature of the change in SICI in MND patients and 
relationship to UMN signs
The most profound abnormality in SICI was the facilitation re-
corded by T- SICI in MND patients with few UMN signs (Figure 6a). 
In contrast, patients with the most pronounced UMN signs had 
almost normal SICI. A- SICI changes were not so strongly related to 
UMNS (Figure 6b), but comparison of the differences in SICI from 
healthy controls, as a function of ISI, indicated that a similar time 
course of relative facilitation was detected by both techniques 
(Figure 6c). This time course, with a single peak at 3 ms, was very 
different from what might have been expected from a simple loss 
of inhibition.
The relationship between SICI measurements and UMNS is 
explored in more detail in Figure 7, where the MND patients 
have been divided into five UMNS subgroups. Mean SICI from 
1 to 3.5 ms shows a progressive change with UMNS that is par-
adoxical, in the sense that SICI is most abnormal in the MND 
patients with the lowest UMNS and becomes more normal as 
F I G U R E  2  Relationship between A- SICI and T- SICI in healthy control subjects. (a) Plot of T- SICI threshold as a percentage of RMT against 
log of A- SICI amplitude as a percentage of RMT1000. Each small cross indicates a measurement on one subject at one of the nine ISIs tested. 
The ellipses indicate the relationships for each ISI. The line is the best fit straight line through the (100, 100) point to the 477 data points: 
T- SICI = 100 − 18.51 × log 10(A- SICI/100). (b) A- SICI amplitude, as a percentage of control, averaged between 1 and 3.5 ms, showing the 
‘floor’ effect. (c) Comparison between T- SICI and A- SICI from 1 to 3.5 ms, after A- SICI values were normalized to A- SICI- T values according 
to the relationship in (a)
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the UMNS gets worse, that is, higher. The correlation between 
these two variables is highly significant (Spearman ρ = 0.565, 
p = 4.3 × 10−6), and even stronger for the peak of facilita-
tion at 3 ms (ρ = 0.634, p = 1.5 × 10−7). On the other hand, 
normalized A- SICI behaves rather differently (Figure 7b). The 
correlation with UMNS is much weaker (ρ = 0.388, p = 0.0021), 
but whereas T- SICI may be normal in the high UMNS patients 
there is still an abnormality in A- SICI- T. It is notable that these 
F I G U R E  3  Dependence of SICI measurements on inter- stimulus interval. (a) A- SICI plotted as the amplitude of conditioned response 
as a percentage of control. (b) A- SICI values normalized to comparable T- SICI thresholds as a percentage of RMT200. (c) T- SICI thresholds. 
Each plot compares the SICI versus ISI relationship for healthy control subjects (black squares), patient controls (blue triangles) and MND 
patients (red circles), showing geometric means ×/÷ geometric SE in (a) and arithmetic means ± SE in (b) and (c) [Colour figure can be viewed 
at wileyonlinelibrary.com]
F I G U R E  4  A- SICI and T- SICI variability 
between subjects. Variability is indicated 
by coefficients of variation (CV, i.e. SD/
control threshold) for (a) normalized 
A- SICI and (b) T- SICI measurements. 
Symbols and colours as in Figure 3: 
healthy control subjects (black squares), 
patient controls (blue triangles) and MND 
patients (red circles) [Colour figure can be 
viewed at wileyonlinelibrary.com]
F I G U R E  5  SICI differences between 
subject groups. SICI averaged from 1 
to 3.5 ms compared between healthy 
controls, patient controls and MND 
patients. (a) Normalized A- SICI. (b) T- 
SICI. Healthy and patient controls were 
not significantly different, by t test; 
asterisks indicate that MND patients 
were significantly different from controls 
(p < 0.00001)
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conspicuous abnormalities in SICI are not accompanied by any 
significant changes in resting motor thresholds (Figure 7c,d), 
so that conditioning stimuli (at 70% RMT200 for T- SICI and A- 
SICI) are similar for all these recordings.
Correlation between SICI measurements and LMN 
findings in MND patients
Threshold tracking SICI also showed paradoxical correlations with 
several LMN- dominated measures of motor neuron degeneration. 
These included MRC sum score (ρ = −0.36, p = 0.0045), fibrilla-
tion potentials/positive sharp waves (e.g., at 2– 3 ms, ρ = 0.489, 
p = 0.00026) and FDI force in the right hand, evaluated with the MRC 
score (ρ = −0.366, p = 0.0036). There was no significant correlation 
between T- SICI parameters and motor amplitude, fasciculations or 
motor unit potential parameters. As with the UMN measures, LMN 
correlations with A- SICI were less significant: A- SICI- T did not cor-
relate with the MRC score or any other EMG or nerve conduction 
studies measures. There was no significant correlation between T- 
SICI or A- SICI and ALSFRS- R.
DISCUSSION
This study is the first to compare threshold tracking and conven-
tional SICI methods in a substantial cohort of patients referred for 
suspicion of ALS or other MNDs. Following our previous compari-
son between three SICI methods in healthy controls [21] it was sus-
pected that our method of assessing SICI by conventional amplitude 
measurements (A- SICI) would provide less variable measurements 
and therefore be better at revealing UMN dysfunction in the pa-
tients than our parallel threshold tracking method (T- SICI). In the 
event, the results have proved more complicated and more interest-
ing than merely revealing differences in discrimination. They have 
shown that the two methods are affected differently by the cortical 
degeneration in MND patients, with different susceptibilities, and 
that the methods are not only good candidates for use as diagnostic 
TA B L E  1  The discrimination of short- interval intracortical 
inhibition patient controls and patients
ISI (ms)
Patient controls (42) vs. 
MND patients (62)
Patient controls (42) 
vs. PMA + MND- U 
(15)
T- SICI A- SICI T- SICI A- SICI
1.0 0.725 0.706 0.785 0.817
1.5 0.728 0.808 0.795 0.859
2.0 0.742 0.820 0.859 0.854
2.5 0.728 0.805 0.871 0.873
3.0 0.746 0.757 0.864 0.863
3.5 0.727 0.735 0.814 0.805
4 0.686 0.704 0.800 0.776
5 0.626 0.630 0.759 0.689
7 0.547 0.569 0.618 0.646
1– 7 0.737 0.732 0.851 0.829
1– 3.5 0.762 0.810 0.867 0.890
2– 3 0.754 0.820 0.881 0.878
Note: Areas under the receiver operating characteristic curves 
comparing patient controls with all motor neuron disease (MND) 
patients and MND patients not classified as amyotrophic lateral 
sclerosis, that is, progressive muscular atrophy (PMA) and unclassified 
MND patients (MND- U).
The bold is the highest of all ISIs and ISI combinations tested.
Abbreviations: A- SICI, short- interval intracortical inhibition measured 
by amplitude changes; ISI, inter- stimulus interval; T- SICI, short- interval 
intracortical inhibition measured by threshold tracking.
F I G U R E  6  SICI facilitation in MND patients. (a) T- SICI as a function of ISI plotted separately for patients with high and low UMN scores, 
compared with healthy controls (HC), showing facilitation rather than inhibition in patients with UMNS from 0 to 5 (triangles), but almost 
normal inhibition in patients with UMNS from 10 to 22 (diamonds). (b) Normalized A- SICI data plotted similarly, showing less facilitation. (c) 
SICI differences from healthy controls, showing similar time courses of relative facilitation. T- SICI and A- SICI- T data for all MND patients in 
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biomarkers in suspected ALS but provide new insights into the likely 
pathophysiological mechanisms involved.
The T- SICI protocol used in this study differs from the one used 
in the previous papers on T- SICI and ALS. Whereas the former stud-
ies used a serial tracking protocol in which ISIs were increased pro-
gressively from 1 to 7 ms and only the changes in threshold were 
tracked, a parallel protocol was used in which thresholds at each ISI 
were tracked independently in parallel. This followed the finding 
that serial tracking results in threshold estimates that are too de-
pendent on the previous one, so that the profile of SICI versus ISI de-
pends strongly on the initial settings and on the direction of change 
of ISI [21]. Parallel tracking is therefore better suited to resolving the 
ISI profiles of SICI abnormality in MND, as illustrated in Figure 6c.
Threshold tracking SICI and A- SICI 
differences and the pathophysiology of MNDs
In healthy subjects there is a consistent relationship between the two 
different SICI measurements as inhibition varies with ISI [21] and this 
is illustrated in Figure 2. In MND, however, this simple logarithmic re-
lationship breaks down, and T- SICI exhibits a greater reduction in SICI 
than expected from the relationship with A- SICI which is most pro-
nounced in patients with the fewest UMN symptoms (Figures 6 and 
7) and therefore most probably in the earliest stages of the disease. 
Our new data provide compelling reasons for concluding that this dis-
crepancy between the two SICI measurements is because the domi-
nant abnormality in these patients is a pathological facilitation rather 
than a reduction in inhibition. In the first place, the threshold changes 
measured by T- SICI in the low UMNS patients is a net facilitation, almost 
as great as the inhibition in healthy controls (Figure 6a). Secondly, the 
differences in SICI between patients and controls, whether measured 
by T- SICI or A- SICI, show a single peak at 3 ms (Figure 6c) rather than 
peaks at 1 and 2.5 ms as in normal SICI. The similarity in time course of 
the threshold changes in Figure 6c indicates that a similar mechanism 
underlies the abnormalities in all the MND patients. The changes in SICI 
in these newly diagnosed MND patients appear similar to those de-
scribed in de novo Parkinson's patients by Shirota et al. [32] They used 
a triple stimulation technique to separate the contributions of short- 
interval cortical facilitation and SICI and concluded that the underlying 
SICI was unchanged, whilst an exaggerated facilitation around the sec-
ond peak (i.e., at 3 ms) caused an apparent loss of inhibition.
A striking feature of the facilitation is the strong positive correla-
tion between T- SICI and the modified Penn UMN score (Figure 7a), 
indicating that the pathological facilitation is reduced as corticospinal 
neurons degenerate. If loss of SICI was a simple sign of UMN dam-
age, then one would have expected a negative correlation between 
T- SICI and UMNS. Instead, patients with little clinical evidence of UMN 
damage showed the greatest drop in SICI, whilst patients with marked 
UMN signs had T- SICI that was normal in extent and time course 
(Figure 6a). The resting motor thresholds did not differ significantly 
between healthy controls and patients and there was no correlation 
between RMT200 and UMNS, so that conditioning stimuli were much 
the same (70% of RMT200) for all T- SICI and A- SICI recordings and all 
the differences were due to differences in the test stimuli. Comparing 
A- SICI and T- SICI for the low UMNS patients, this means that there 
was a subset of cortical motor neurons that experienced sufficient 
facilitation to generate a 200 μV MEP with a stimulus well below 
F I G U R E  7  Paradoxical relationship between SICI and UMN score in MND patients. (a) Mean T- SICI from 1 to 3.5 ms comparing healthy 
controls with progressive changes in UMN score in subgroups of MND patients, with the most abnormal SICI found in patients with the 
fewest UMN signs. (b) Corresponding changes in normalized A- SICI. (c) RMT200 values for the same recordings as in (a), showing no 
significant differences. (d) TS1 mV values for the recordings in (b). In each plot, horizontal lines are medians and bars indicate interquartile 
ranges. Asterisks indicate significant differences from healthy controls by Mann– Whitney U test: NS, p > 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001; *****p < 0.00001. Spearman's rho values also shown for correlations between UMNS and SICI or RMT for all 62 MND 
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RMT200. On the other hand, the stronger test stimuli used for A- SICI 
recruited neurons with much less facilitation, so that on average there 
was a small net inhibition. Comparing T- SICI between patients with 
increasing UMN scores (Figure 7a), the simplest explanation for the 
apparently paradoxical relationship is that the cortical motor neurons 
experiencing most facilitation progressively degenerate (consistent 
with an excitotoxic mechanism), whilst those experiencing inhibition 
survive. The changes in A- SICI are less pronounced since the stronger 
stimuli used sample a larger proportion of motor neurons.
Our results confirm an earlier observation on patients with 
SOD- 1 mutations that T- SICI can be abolished before signs of ALS 
develop [33]. They indicate that the reason for the high sensitivity 
of T- SICI in detecting early UMN dysfunction is because threshold 
measurements can best reveal when only a few cortical motor neu-
rons are affected.
Threshold tracking SICI and A- SICI as diagnostic 
biomarkers for ALS
Threshold tracking SICI has been shown to be reduced in ALS in sev-
eral studies and has been proposed as a diagnostic [10,16,18,34,35] 
and prognostic [24] biomarker for ALS. However, a comparison with 
conventional A- SICI has been lacking. Taking the MND group of pa-
tients as a whole, it was found that the A- SICI method produces less 
variable SICI measurements in all three groups of subjects than the T- 
SICI method (Figure 4), and it provided slightly better discrimination 
between the MND patients and patient controls (Table 1). However, 
as diagnostic biomarkers of UMN pathology in MND patients that 
did not fall into any ALS category, both SICI methods provided simi-
larly excellent discrimination from the patient controls.
There has been frequent discussion in the literature as to how broad 
the definition of ALS should be [18] and the most widely accepted crite-
ria have changed with time [6,8]. The ALS criteria have been simplified 
in a recent proposal, where TMS has been proposed as supportive evi-
dence of UMN dysfunction [36]. Our results strongly support the con-
tention that the requirement for a positive diagnosis that there should 
be clinical UMN and LMN dysfunction in different body regions is too 
restrictive. Loss of T- SICI or A- SICI, even in the absence of clinical UMN 
signs, should be accepted as supporting evidence of UMN pathology, to 
allow earlier diagnosis and increased recruitment into therapeutic trials, 
especially in the early stages of the disease when treatments are likely 
to be most effective [10].
CONCLUSION
It has been found that both A- SICI and T- SICI are sensitive early indica-
tors of UMN dysfunction in patients referred for suspicion of ALS, with 
T- SICI most abnormal before UMN signs have developed. Arguments 
that SICI should be accepted as an aid to the early diagnosis of ALS are 
therefore strongly supported [10,18,19,35]. On the other hand, since 
T- SICI becomes more normal as signs of disease progression increase, 
it may not be suitable for monitoring potential ALS treatments.
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